Fluvoxamine Shows Promise in Lightening Long COVID Fatigue

A recent randomized trial conducted in Brazil examined whether two widely available medications—fluvoxamine, an inexpensive antidepressant, and metformin, a common diabetes drug—could reduce the persistent tiredness that follows a COVID‑19 infection.

Study Design

• Participants: Nearly 400 adults with fatigue lasting three months or more after COVID‑19.
• Intervention: Random assignment to receive either fluvoxamine, metformin, or a placebo for two months.
• Outcome Measure: Self‑reported exhaustion levels.

Key Findings

Implications for Practice

• Evidence‑based option: Fluvoxamine offers a tangible treatment avenue for patients struggling with the most crippling symptom of long COVID.
• Safety and accessibility: The drug’s established safety profile and global availability could accelerate clinical adoption.

Unanswered Questions

• Patient subgroups: Which patients benefit most remains unclear.
• Mechanism of action: How fluvoxamine dampens fatigue is still unknown.
• Optimal dosing and timing: Future studies should refine dosage, initiation timing, and underlying biological pathways.

Conclusion

This trial represents a significant step toward practical solutions for long‑COVID fatigue, providing hope that an existing medication can improve the quality of life for thousands still battling post‑viral exhaustion.